A Phase I, Open-Label, Single-Period Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification After Oral Administration of [14C]AZD4831 in Healthy Male Subjects
Latest Information Update: 19 Jan 2023
At a glance
- Drugs Mitiperstat (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 13 Jan 2023 Results(n=6) assessing the mass balance and disposition of AZD4831Following Administration of an Oral Radiolabeled Microtracer Dose in Humans published in the Drug Metabolism and Disposition
- 24 Aug 2020 Status changed from active, no longer recruiting to completed.
- 28 Jul 2020 Planned End Date changed from 10 Aug 2020 to 28 Jul 2020.